Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14850591 | 0.90 | HTT (0.68) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL22168449 | 0.89 | HTT (0.66) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL19400320 | 0.89 | HTT (0.66) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL6648982 | 0.87 | HTT (0.62) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL7514786 | 0.85 | HTT (0.73) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL17079191 | 0.85 | HTT (0.64) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5314068 | 0.85 | HTT (0.64) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8426731 | 0.84 | ALDH1A1 (0.60) | HTTLMNASMN1; SMN2L3MBTL1PRSS1 | |
| SCHEMBL5217172 | 0.84 | HTT (0.68) | HTTLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8241625 | 0.84 | MEN1 (0.62) | HTTLMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1780841-A | 5,7-diaminopyrazolo[4,3-d]pyrimidines useful in the traetment of hypertension | PFIZER LTD (GB) | 2006-05-31 | — | — | CN | disclosed |
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | BRISTOL- MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-03-31 | — | — | US | disclosed |
| US-20050020547-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
| EP-1097719-B1 | NEP inhibitors for the treatment of female sexual dysfunction | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | PFIZER INC | 2004-12-16 | — | — | US | disclosed |
| EP-1481667-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6734186-B1 | PHOSPHODIESTERASE 2 INHIBITOR | PFIZER INC. | 2004-05-11 | — | — | US | disclosed |
| CN-1438991-A | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER CIMITED (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| EP-1097707-A1 | Treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097718-A1 | NPY antagonists for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097706-A1 | Phosphodiesterase inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
| EP-1097719-A1 | NEP inhibitors for the treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245535-A1 | Sulfonyl amide inhibitors of calcium channel function | CACNA1F, CACNA1A, CACNA1D | HTT 2734/4885LMNA 535/4885SMN1; SMN2 2190/4885 |
| US-20040254153-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | HTT 2660/4885LMNA 4218/4885SMN1; SMN2 2007/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | HTT 3248/4885LMNA 2711/4885SMN1; SMN2 2805/4885 |
| US-20050020547-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | HTT 2660/4885LMNA 4218/4885SMN1; SMN2 2007/4885 |
| US-20050070499-A1 | Compounds for the treatment of female sexual dysfunction | FSHR, SHBG, PDE3A | HTT 2660/4885LMNA 4218/4885SMN1; SMN2 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.